Scientific presentations including slides, posters and abstracts
Iaci JF, Grundman M, Hernandez NAS, et al. Alzheimer’s Disease Pivotal Trial Design for Zervimesine Following an End-of-Phase 2 Meeting with FDA. Poster presentation at 2025 Clinical Trials in Alzheimer’s Disease (CTAD); San Diego, CA
Galvin JE, Hambe ME, Iaci JF, et al. Phase 2 Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies. Podium presentation at 2025 Alzheimer’s Association International Conference (AAIC); Toronto, Ontario, Canada
Phase 2 Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies Read More »
Lizama BN, Pandey K, Cho E, et al. Exploratory CSF Proteomic Analysis of a Pre-specified pTau217 Subgroup from the SHINE Clinical Trial Identifies Biomarkers Correlated with Cognitive Improvement in Alzheimer’s Disease Patients Treated with Zervimesine. Poster presented at 2025 Alzheimer’s Association International Conference (AAIC); Toronto, Ontario, Canada
Grundman M, Catalano S, Hamby ME, et al. Zervimesine (CT1812) Treatment Benefits Patients with Lower Baseline Plasma p-tau217 Across the Mild-to-Moderate AD Spectrum. Poster presented at 2025 Alzheimer’s Association International Conference (AAIC); Toronto, Ontario, Canada
Lizama BN, DiCaro V, Cho E, et al. Plasma Proteomic Analysis of a Biomarker-defined Subpopulation in the SHINE Ph2 Trial to Identify Molecular Correlates to the Favorable Decrease in the Neuroinflammatory Marker GFAP with Zervimesine in Alzheimer’s Disease Participants. Poster presented at 2025 Alzheimer’s Association International Conference (AAIC); Toronto, Ontario, Canada
Knezovich N, Thiel JK, Lizama BN, et al. Sigma-2 receptor modulators including CT1812 modulate low density lipoprotein uptake in primary rat neurons. Poster presented at Keystone 2025; Whistler, BC, Canada
Thiel JK, Cho E, Caggiano AO, et al. CT1812 preserves neurons and decreases levels of neurodegeneration biomarker NfL in disease-relevant neuronal model. Poster presented at Keystone 2025; Whistler, BC, Canada
Cho E, Thiel JK, Caggiano AO, et al. The sigma-2 receptor modulator and investigational therapeutic CT1812 is neuroprotective against 4-HNE-induced cell death in a disease-relevant neuronal model. Poster presented at Keystone 2025; Whistler, BC, Canada
Lizama BN, Reaver A, Di Caro V, et al. Delineating Mechanisms of Sigma-2 Receptor Modulators in Regulating Retinal Pigment Epithelial Lipid Uptake. Poster presented at ARVO 2025; Salt Lake City, UT
Hamby ME, Lizama BN, Reaver A, et al. Sigma-2 Receptor Modulation Promotes Retinal Pigment Epithelial Cell Survival Following Chronic 7-Ketocholesterol Exposure. Poster presented at ARVO 2025; Salt Lake City, UT
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
